About this episode

The episode discusses the new ADHD medication Simtriyo and its recent FDA approval.

Welcome back! Today, we are talking about Simtriyo, which has generated a lot of media attention recently given a newly minted FDA approval for ADHD. References https://pmc.ncbi.nlm.nih.gov/articles/PMC12314114/ https://pmc.ncbi.nlm.nih.gov/articles/PMC12379780/ https://pubmed.ncbi.nlm.nih.gov/31776871/ https://pubmed.ncbi.nlm.nih.gov/40619095/ https://pubmed.ncbi.nlm.nih.gov/28731336/ https://pmc.ncbi.nlm.nih.gov/articles/PMC9426730/

People in this episode

Hosts: Dr. Tanner Hewitt, Dr. Larry Wang, Dr. Bradley Miller

Topics covered

• ADHD
• medication
• FDA approval
• mental health
• pharmaceuticals

Keywords

• Centanafadine
• Simtriyo
• ADHD
• FDA approval
• medication
• mental health
• pharmaceuticals

Mentioned in this episode

Organizations: FDA

Products: Centanafadine, Simtriyo

More episodes of PsychRounds: The Psychiatry Podcast

• Landmark Studies: The STAR*D Trial · September 2, 2026 · 28 min
• Dogs in Mental Health with Dr. Nancy Gee: A Biopsychosocial Approach · August 19, 2026 · 55 min
• Landmark Studies: The CATIE Trial · July 22, 2026 · 22 min

Explore listener stats, chart rankings, contacts and more on the PsychRounds: The Psychiatry Podcast podcast page.